Article
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor.
JCO precision oncology - 1 Jan 2021
Luo Jia, Makhnin Alex, Tobi Yosef, Ahn Linda, Hayes Sara A, Iqbal Afsheen, Ng Kenneth, Arcila Maria E, Riely Gregory J, Kris Mark G, Yu Helena A
Abstract excerpt
Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation of this pathway may be a mechanism of acquired resistance. Therefore, MEK inhibition with trametinib and an EGFR TKI may resensitize tumors with acquired resistance. Limited targeted therapies are available after...
Topics
- Adenocarcinoma of Lung
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Humans
- Lung Neoplasms
- Male
- Middle Aged